Trial Profile

A randomized Phase 2 clinical study evaluating NBTXR3 for the treatment of patients with stage 3,unresectable non-small cell lung cancer

Status: Planning

Phase of Trial: Phase II

Latest Information Update: 16 May 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

16 May 2024 New trial record
14 May 2024 According to NANOBIOTIX media release, the U.S. Food and Drug Administration (US FDA) issued a Study May Proceed Letter for this randomized Phase 2 study evaluating NBTXR3 for the treatment of patients with stage 3, unresectable non-small cell lung cancer.
14 May 2024 According to NANOBIOTIX media release, the Investigational New Drug (IND) application submitted by the Johnson & Johnson Enterprise Innovation Inc., has received approval to support the trial.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com